SCHEMBL2174272

SCHEMBL2174272

C[C@]1(C(=O)N2CCN(c3ccccc3)CC2)N(C(=O)O)C[C@@H](Oc2cccc(F)c2)C[C@]1(C)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.41
ENPP2 Q13822 3/20 0.40
FAAH O00519 3/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HRH3 Q9Y5N1 2/20 0.39
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MGLL Q99685 2/20 0.38
ABHD6 Q9BV23 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173082 0.83 ALDH1A1 (0.46) LMNAALDH1A1TSHRSMN1; SMN2MAPT
SCHEMBL2173080 0.80 ALDH1A1 (0.44) LMNAALDH1A1TSHRSMN1; SMN2MAPT
SCHEMBL2177052 0.79 LMNA (0.43) LMNAALDH1A1TSHRSMN1; SMN2MAPT
SCHEMBL2172932 0.79 HRH3 (0.40) ENPP2HRH3
SCHEMBL2173178 0.77 LMNA (0.49) LMNAALDH1A1TSHRSMN1; SMN2MAPT
SCHEMBL2173564 0.77 LMNA (0.49) LMNAALDH1A1TSHRSMN1; SMN2MAPT
SCHEMBL2177320 0.77 LMNA (0.41) LMNAALDH1A1TSHRSMN1; SMN2MAPT
SCHEMBL2176908 0.76 ALDH1A1 (0.43) LMNAALDH1A1TSHRSMN1; SMN2MAPT
SCHEMBL4476420 0.75 GPR119 (0.39) LMNAALDH1A1TSHRMAPTRAB9A
SCHEMBL2174752 0.72 ADAM10 (0.37) LMNAALDH1A1TSHRMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 ALOX15 677/4885ENPP2 377/4885FAAH 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.